755 related articles for article (PubMed ID: 23351086)
1. Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.
Herr HW; Dalbagni G
BJU Int; 2013 May; 111(6):984-7. PubMed ID: 23351086
[TBL] [Abstract][Full Text] [Related]
2. Letter: intravesical Bacille Calmette-Guerin (BCG) in immunologically compromised patients with bladder cancer--reply.
Hwang M; Banerji J; Neill M
BJU Int; 2013 Dec; 112(8):E435. PubMed ID: 24284001
[No Abstract] [Full Text] [Related]
3. Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guérin relapsing non-muscle-invasive bladder cancer.
Matsumoto K; Kikuchi E; Shirakawa H; Hayakawa N; Tanaka N; Ninomiya A; Miyajima A; Nakamura S; Oya M
BJU Int; 2012 Dec; 110(11 Pt B):E508-13. PubMed ID: 22574662
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment.
Kakiashvili DM; van Rhijn BW; Trottier G; Jewett MA; Fleshner NE; Finelli A; Azuero J; Bangma CH; Vajpeyi R; Alkhateeb S; Hanna S; Kostynsky A; Kuk C; Van Der Kwast TH; Zlotta AR
BJU Int; 2011 Feb; 107(4):540-6. PubMed ID: 21276177
[TBL] [Abstract][Full Text] [Related]
5. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
6. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of Bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer.
Shirakawa H; Kikuchi E; Tanaka N; Matsumoto K; Miyajima A; Nakamura S; Oya M
BJU Int; 2012 Sep; 110(6 Pt B):E216-21. PubMed ID: 22313616
[TBL] [Abstract][Full Text] [Related]
8. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
Prasad SM; Eyre S; Loughlin KR
Hosp Pract (1995); 2013; 41(4):31-9. PubMed ID: 24145587
[TBL] [Abstract][Full Text] [Related]
9. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
Fujimoto K; Chihara Y; Kondo H; Hirao Y
Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
[TBL] [Abstract][Full Text] [Related]
10. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
11. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
12. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
Barlow L; McKiernan J; Sawczuk I; Benson M
BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012
[TBL] [Abstract][Full Text] [Related]
13. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
15. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.
Zieger K; Jensen KM
Scand J Urol Nephrol; 2011 Dec; 45(6):411-8. PubMed ID: 21793636
[TBL] [Abstract][Full Text] [Related]
16. Intravesical bacille Calmette-Guérin eradicates bacteriuria in antibiotic-naïve bladder cancer patients.
Herr HW
Eur Urol; 2013 May; 63(5):832-5. PubMed ID: 22921719
[TBL] [Abstract][Full Text] [Related]
17. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
18. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
Boorjian SA; Zhu F; Herr HW
BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
[TBL] [Abstract][Full Text] [Related]
19. The effect of fibrin clot inhibitors on the immunomodulatory efficacy of Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer.
Lipsky MJ; Badalato GM; Motamedinia P; Hruby GW; McKiernan JM
Urology; 2013 Jun; 81(6):1273-8. PubMed ID: 23528913
[TBL] [Abstract][Full Text] [Related]
20. Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma.
Alvarez-Múgica M; Fernández-Gómez JM; Cebrian V; Fresno F; Escaf S; Sánchez-Carbayo M
Eur Urol; 2013 Feb; 63(2):364-70. PubMed ID: 22682992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]